Pipelines
SH-114
A treatment for Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
DISEASE STATE OVERVIEW
SH-114 is a preferred regimen for both Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in various mono & combination settings.
- Approximately 10,000 patients in the US are diagnosed with MDS per year1
- Approximately 20,000 patients in the US are diagnosed with AML per year1
Regulatory Status
Coming soon.
1 American Cancer Society. Cancer Facts & Figures, 2021.